Form 4: Boston Scientific Executive Exercises Options and Sells Shares Under 10b5-1 Plan

A Boston Scientific executive, John Bradley Sorenson, exercised stock options and sold shares under a pre-established 10b5-1 trading plan.

Summary

• John Bradley Sorenson, an Executive Vice President at Boston Scientific, executed transactions involving the company's stock on November 8, 2024.
• Sorenson exercised stock options to acquire 17,362 shares of common stock at a price of $24.55 per share.
• He then sold 30,580 shares of common stock at a weighted average price of $87.6577 per share, with individual sales ranging from $87.324 to $87.94.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
• Following these transactions, Sorenson directly owns 39,706 shares of Boston Scientific common stock.

Sentiment

Score: 7

Explanation: The document reflects routine executive stock transactions under a pre-established plan, which is generally neutral. The use of a 10b5-1 plan suggests a proactive approach to compliance, which is a positive.

Industry Context

This is a routine filing related to executive stock transactions and is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, such as Medtronic (MDT) and Abbott Laboratories (ABT), to manage their stock transactions.
• The vesting schedule of the stock options is typical for executive compensation packages, often with annual vesting over a period of years.
• The reported sale price range is consistent with the market price of Boston Scientific stock at the time of the transaction.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.
• The sale of shares by an executive could be perceived as a negative signal by some investors, but the use of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Boston Scientific, stock options, insider trading, Form 4, 10b5-1 plan, executive compensation, share sale